Literature DB >> 24306216

The prevalence of low serum vitamin B-12 status in the absence of anemia or macrocytosis did not increase among older U.S. adults after mandatory folic acid fortification.

Yan Ping Qi1, Ann N Do, Heather C Hamner, Christine M Pfeiffer, Robert J Berry.   

Abstract

Whether folic acid fortification and supplementation at the population level have led to a higher prevalence of vitamin B-12 deficiency in the absence of anemia remains to be examined among a nationally representative sample of older U.S. adults. We assessed the prevalence of low vitamin B-12 status in the absence of anemia or macrocytosis before and after fortification among adults aged >50 y using cross-sectional data from the NHANES 1991-1994 (prefortification) and 2001-2006 (postfortification). We compared the prefortification and postfortification prevalence of multiple outcomes, including serum vitamin B-12 deficiency (<148 pmol/L) and marginal deficiency (148-258 pmol/L) with and without anemia (hemoglobin <130 g/L for men, <120 g/L for women) and with and without macrocytosis (mean cell volume >100 fL) using multinomial logistic regression, adjusting for age, sex, ethnicity, body mass index, C-reactive protein, and vitamin B-12 supplement use. Prefortification and postfortification serum vitamin B-12 deficiency without anemia [4.0 vs. 3.9%; adjusted prevalence ratio (aPR) (95% CI): 0.98 (0.67, 1.44)] or without macrocytosis [4.2 vs. 4.1%; aPR (95% CI): 0.96 (0.65, 1.43)] remained unchanged. Marginal deficiency without anemia [25.1 vs. 20.7%; aPR (95% CI): 0.82 (0.72, 0.95)] or without macrocytosis [25.9 vs. 21.3%; aPR (95% CI): 0.82 (0.72, 0.94)] were both significantly lower after fortification. After fortification, higher folic acid intake was associated with a lower prevalence of low serum B-12 status in the absence of anemia or macrocytosis. Results suggest that the prevalence of low serum B-12 status in the absence of anemia or macrocytosis among older U.S. adults did not increase after fortification. Thus, at the population level, we found no evidence to support concerns that folic acid adversely affected the clinical presentation of vitamin B-12 deficiency among older adults.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24306216      PMCID: PMC5291239          DOI: 10.3945/jn.113.183095

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  35 in total

1.  Historical review: a history of pernicious anaemia.

Authors:  I Chanarin
Journal:  Br J Haematol       Date:  2000-11       Impact factor: 6.998

Review 2.  Progress in understanding the pathogenesis of the anemia of chronic disease.

Authors:  R T Means; S B Krantz
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

3.  Neurologic aspects of cobalamin deficiency.

Authors:  E B Healton; D G Savage; J C Brust; T J Garrett; J Lindenbaum
Journal:  Medicine (Baltimore)       Date:  1991-07       Impact factor: 1.889

4.  The development and progression of subacute combined degeneration of the spinal cord in patients with pernicious anemia treated with synthetic pteroylglutamic (folic) acid.

Authors:  J F ROSS; H BELDING; B L PAEGEL
Journal:  Blood       Date:  1948-01       Impact factor: 22.113

5.  Proportion of individuals with low serum vitamin B-12 concentrations without macrocytosis is higher in the post folic acid fortification period than in the pre folic acid fortification period.

Authors:  Kelly F Wyckoff; Vijay Ganji
Journal:  Am J Clin Nutr       Date:  2007-10       Impact factor: 7.045

6.  Development of an approach for estimating usual nutrient intake distributions at the population level.

Authors:  P M Guenther; P S Kott; A L Carriquiry
Journal:  J Nutr       Date:  1997-06       Impact factor: 4.798

7.  Circulating unmetabolized folic acid and 5-methyltetrahydrofolate in relation to anemia, macrocytosis, and cognitive test performance in American seniors.

Authors:  Martha Savaria Morris; Paul F Jacques; Irwin H Rosenberg; Jacob Selhub
Journal:  Am J Clin Nutr       Date:  2010-03-31       Impact factor: 7.045

8.  Unexplained decline in the prevalence of anemia among US children and women between 1988-1994 and 1999-2002.

Authors:  Sarah E Cusick; Zuguo Mei; David S Freedman; Anne C Looker; Cynthia L Ogden; Elaine Gunter; Mary E Cogswell
Journal:  Am J Clin Nutr       Date:  2008-12       Impact factor: 7.045

Review 9.  Does folic acid harm people with vitamin B12 deficiency?

Authors:  C J Dickinson
Journal:  QJM       Date:  1995-05

Review 10.  Biomarkers of vitamin B-12 status in NHANES: a roundtable summary.

Authors:  Elizabeth A Yetley; Christine M Pfeiffer; Karen W Phinney; Regan L Bailey; Sheena Blackmore; Jay L Bock; Lawrence C Brody; Ralph Carmel; L Randy Curtin; Ramón A Durazo-Arvizu; John H Eckfeldt; Ralph Green; Jesse F Gregory; Andrew N Hoofnagle; Donald W Jacobsen; Paul F Jacques; David A Lacher; Anne M Molloy; Joseph Massaro; James L Mills; Ebba Nexo; Jeanne I Rader; Jacob Selhub; Christopher Sempos; Barry Shane; Sally Stabler; Patrick Stover; Tsunenobu Tamura; Alison Tedstone; Susan J Thorpe; Paul M Coates; Clifford L Johnson; Mary Frances Picciano
Journal:  Am J Clin Nutr       Date:  2011-05-18       Impact factor: 7.045

View more
  13 in total

1.  Folate and neural tube defects: The role of supplements and food fortification.

Authors:  Noam Ami; Mark Bernstein; François Boucher; Michael Rieder; Louise Parker
Journal:  Paediatr Child Health       Date:  2016-04       Impact factor: 2.253

2.  Diagnostic value of blood tests for occult causes of initially idiopathic small-fiber polyneuropathy.

Authors:  Magdalena Lang; Roi Treister; Anne Louise Oaklander
Journal:  J Neurol       Date:  2016-10-11       Impact factor: 4.849

Review 3.  Lack of historical evidence to support folic acid exacerbation of the neuropathy caused by vitamin B12 deficiency.

Authors:  Robert J Berry
Journal:  Am J Clin Nutr       Date:  2019-09-01       Impact factor: 7.045

4.  Modelling the impact of mandatory folic acid fortification of bread or flour in Ireland on the risk of occurrence of NTD-affected pregnancies in women of childbearing age and on risk of masking vitamin B12 deficiency in older adults.

Authors:  Laura Kehoe; Janette Walton; Sinead M Hopkins; Breige A McNulty; Anne P Nugent; Albert Flynn
Journal:  Eur J Nutr       Date:  2019-10-23       Impact factor: 5.614

5.  Folic acid causes higher prevalence of detectable unmetabolized folic acid in serum than B-complex: a randomized trial.

Authors:  Rima Obeid; Susanne H Kirsch; Sarah Dilmann; Cosima Klein; Rudolf Eckert; Jürgen Geisel; Wolfgang Herrmann
Journal:  Eur J Nutr       Date:  2015-05-06       Impact factor: 5.614

6.  Retrospective Assessment of Cost Savings From Prevention: Folic Acid Fortification and Spina Bifida in the U.S.

Authors:  Scott D Grosse; Robert J Berry; J Mick Tilford; James E Kucik; Norman J Waitzman
Journal:  Am J Prev Med       Date:  2016-01-11       Impact factor: 5.043

7.  B vitamin blood concentrations and one-carbon metabolism polymorphisms in a sample of Italian women and men attending a unit of transfusion medicine: a cross-sectional study.

Authors:  Renata Bortolus; Francesca Filippini; Silvia Udali; Marianna Rinaldi; Sabrina Genesini; Giorgio Gandini; Martina Montagnana; Francesca Chiaffarino; Giuseppe Lippi; Patrizia Pattini; Gelinda De Grandi; Oliviero Olivieri; Fabio Parazzini; Simonetta Friso
Journal:  Eur J Nutr       Date:  2020-12-29       Impact factor: 5.614

8.  Fortification of wheat and maize flour with folic acid for population health outcomes.

Authors:  Elizabeth Centeno Tablante; Helena Pachón; Heather M Guetterman; Julia L Finkelstein
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

Review 9.  Contemporary issues surrounding folic Acid fortification initiatives.

Authors:  Jeong-Hwa Choi; Zoe Yates; Martin Veysey; Young-Ran Heo; Mark Lucock
Journal:  Prev Nutr Food Sci       Date:  2014-12-31

Review 10.  B Vitamins and the Brain: Mechanisms, Dose and Efficacy--A Review.

Authors:  David O Kennedy
Journal:  Nutrients       Date:  2016-01-27       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.